11 – 20 of 26
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
Familial characteristics of Waldenström's macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL): A population-based study in Sweden
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.166-166(
- Contribution to journal › Published meeting abstract
-
Mark
Increased risk of monoclonal gammopathy of undetermined significance (MGUS) and lymphoid tumors among first-degree relatives of MGUS cases
2008) 17th Annual Meeting of the International-Genetic-Epidemiology-Society In Genetic Epidemiology 32(7). p.691-691(
- Contribution to journal › Published meeting abstract
-
Mark
Family history of cancer as a risk factor for second malignancies after Hodgkin's lymphoma
(
- Contribution to journal › Article
-
Mark
Long Term Efficacy And Tolerability Of Anagrelide In Myeloproliferative Disorders
2008) 13th Congress of the European-Hematology-Association In Haematologica-The Hematology Journal 93. p.0746-0746(
- Contribution to journal › Published meeting abstract
- 2005
-
Mark
Leukotriene B-4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells
(
- Contribution to journal › Article
-
Mark
High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma
(
- Contribution to journal › Article
-
Mark
Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience
(
- Contribution to journal › Article
-
Mark
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: Long-term follow-up
(
- Contribution to journal › Article
- 2004
-
Mark
A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma
(
- Contribution to journal › Article
-
Mark
Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders
(
- Contribution to journal › Article